AUPH: Aurinia Pharmaceuticals Inc Company Value to Net Income

Aurinia Corp - graphic logo of issuer AUPH

Aurinia Pharmaceuticals (AUPH) is implementing digital biodata monitoring to accelerate trials of immune drugs. The company's fundamental P/E multiple on GURU.Markets shows that the current status is 6.50, attributing this to Lupkynis sales growth and share buybacks. The business's financial stability is confirmed by a steady cash flow that fully covers capital expenditures and operating expenses.

Aurinia Pharmaceuticals Inc. (AUPH) Price to Earnings Ratio: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Aurinia Corp (AUPH)

- price and consensus price forecast:
Comprehensive company analysis:Aurinia Pharmaceuticals Inc. AUPH
Signature product of Aurinia Pharma

The resilience of Aurinia Pharmaceuticals (AUPH) is driven by the rollout dynamics of its lupus nephritis therapy and a substantial liquidity reserve. The ratio of market capitalization to confirmed net income, as reflected in the company's P/E history, allows investors to assess the cost per unit of earnings and the speed of market revaluation following the publication of 10-K or 10-Q reports, revealing the balance between current yield and the risk of overpayment.

Key competitors

P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Price to Earnings Ratio|Grifols Biemat (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotechnologies|Price to Earnings Ratio CLDX|P/E Multiple biocryst.com|Price to Earnings Ratio Vera Pharma (VERA)|Dianthus Therapeutics, Inc. - Price to Earnings Multiple|P/E Multiple PHVS (pharvaris.com)|AbCellera Bio (ABCL) - Market Cap to Earnings|TRML: Price to Earnings Ratio|Market Cap to Net Income PGEN|PHAR: P/E Multiple|Market Cap to Earnings Nektar Therapeutics Inc (NKTR)|Price to Earnings Ratio UPB|Price to Earnings Multiple ZBIO (Zenas Biopharma, Inc.)|Price to Earnings Ratio IMNM (Immunome Bio)|Business Payback Period Gossamer Bio, Inc.|P/E Multiple KALV (KalVista Pharma)|Septerna, Inc. (SEPN) - Market Cap to Earnings|PVLA - Price to Earnings Ratio|SVRA - P/E Multiple|Rigel Pharmaceuticals Inc (RIGL) - Price to Earnings Ratio|ANAB - Business Payback Period|Price to Earnings Ratio ATXS|ENGN: Company Value to Net Income|Price to Earnings Ratio RAPT Therapeutics (RAPT)|JBIO (Aerovate) - Company Value to Net Income|P/E Multiple ACRS (Aclaris Therapeutics)|Company Value to Net Income KYTX|Tiziana Life Sciences - P/E Multiple|CABA: Price to Earnings Ratio|VTYX: P/E Multiple|THTX (Theratechnologies, Inc) - Price to Earnings Ratio|AVTX (Avalo Therapeutics, Inc.) - P/E Multiple|P/E Multiple Eledon Pharmaceuticals|Price to Earnings Ratio Agenus Inc. (AGEN)|Price to Earnings Ratio Climb Bio Inc. CLYM|P/E Multiple ZURA (Zura Bio Ltd)|ATYR - Price to Earnings Ratio|ADAG - Price to Earnings Ratio|IMA - P/E Multiple|STTK: P/E Multiple|Equillium Bio (EQ) - P/E Multiple|CNTB (connectbiopharm.com) - P/E Multiple|IMUX: Company Value to Net Income|P/E Multiple ATRA|P/E Multiple InflaRx NV (IFRX)|X4 Pharmaceuticals, Inc. (XFOR) - Market Cap to Net Income|P/E Multiple adicetbio.com ACET|Celularity - P/E Multiple|Company Value to Net Income INMB (INmune Bio Corp)|BRNS (Barinthus Bio) - Price to Earnings Ratio|Market Cap to Net Income KZR (Kezar Life Sciences)|Price to Earnings Ratio SAB Biotherapeutics Inc.|Akari Therapeutics Plc - Market Cap to Net Income|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd.)|Price to Earnings Ratio Q32 Bio Inc QTTB|Price to Earnings Ratio geovax.com GOVX|P/E Multiple edesabiotech.com EDSA|iBio Corporation - P/E Multiple|Company Value to Net Income CARM (carismatx.com)|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Bolt Bio (BOLT) - P/E Multiple|HCWB (HCW Biologics Inc) - P/E Multiple|Price to Earnings Ratio Aptevo Therapeutics (APVO)|P/E Multiple AIM|Market Price to Net Income Ratio ADTX|P/E Multiple GRI (GRI Bio Corporation)|P/E Multiple XORTX Corp XRTX|HIND - Price to Earnings Ratio|Revelation Biosciences (REVB) - Price to Earnings Ratio|INDP (Indaptus Therapeutics, Inc.) - Price to Earnings Ratio|Scinai Immunotherapeutics Ltd (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|affimed.com - Market Cap to Net Income|Price to Earnings Ratio allakos.com (ALLK)|P/E Multiple HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Price to Earnings Ratio|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple